S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
Log in

NASDAQ:RVNC - Revance Therapeutics Stock Price, Forecast & News

$22.46
+0.11 (+0.49 %)
(As of 01/17/2020 04:00 PM ET)
Today's Range
$22.10
Now: $22.47
$22.68
50-Day Range
$15.75
MA: $17.18
$22.95
52-Week Range
$9.88
Now: $22.47
$23.43
Volume628,377 shs
Average Volume938,811 shs
Market Capitalization$1.01 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.23
Revance Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development, manufacture, and commercialization of novel neuromodulators for various aesthetic and therapeutic indications. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which is in phase III clinical trials to treat glabellar (frown) lines and cervical dystonia; and in phase II clinical trials for the treatment of plantar fasciitis, adult upper limb spasticity, and chronic migraine. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RVNC
CUSIPN/A
Phone510-742-3400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.73 million
Book Value$3.94 per share

Profitability

Net Income$-142,570,000.00

Miscellaneous

Employees170
Market Cap$1.01 billion
Next Earnings Date2/25/2020 (Estimated)
OptionableOptionable

Receive RVNC News and Ratings via Email

Sign-up to receive the latest news and ratings for RVNC and its competitors with MarketBeat's FREE daily newsletter.


Hidden Income 'hack' (Ad)


This hidden income strategy was just leaked and it can be yours now. It goes in depth about how you can start off with a small account and turn that into your own weekly paycheck. Learn how you can GAIN that extra advantage over what others aren't doing.

Revance Therapeutics (NASDAQ:RVNC) Frequently Asked Questions

What is Revance Therapeutics' stock symbol?

Revance Therapeutics trades on the NASDAQ under the ticker symbol "RVNC."

How were Revance Therapeutics' earnings last quarter?

Revance Therapeutics Inc (NASDAQ:RVNC) posted its quarterly earnings data on Monday, November, 4th. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, hitting the Zacks' consensus estimate of ($0.96). The biopharmaceutical company had revenue of $0.05 million for the quarter, compared to analysts' expectations of $0.40 million. View Revance Therapeutics' Earnings History.

When is Revance Therapeutics' next earnings date?

Revance Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Revance Therapeutics.

What price target have analysts set for RVNC?

8 brokerages have issued 12 month target prices for Revance Therapeutics' stock. Their forecasts range from $20.00 to $50.00. On average, they expect Revance Therapeutics' share price to reach $29.86 in the next year. This suggests a possible upside of 32.9% from the stock's current price. View Analyst Price Targets for Revance Therapeutics.

What is the consensus analysts' recommendation for Revance Therapeutics?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Revance Therapeutics in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Revance Therapeutics.

What are Wall Street analysts saying about Revance Therapeutics stock?

Here are some recent quotes from research analysts about Revance Therapeutics stock:
  • 1. According to Zacks Investment Research, "Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS® peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform. " (1/15/2020)
  • 2. Mizuho analysts commented, "We estimate a floor valuation of $17/share which includes: additional dilutive financing, Fosun deal, no credit for therapeutics, poor performance in U.S. aesthetics. With credit for therapeutics and fair aesthetic assumptions, we see ~180%+ upside to our base case $37 PT." (4/24/2019)
  • 3. HC Wainwright analysts commented, "Our $25 price target for Revance is based on our sum of the parts NPV valuation based on each of RT-002’s targeted indications. Our DCF model utilizes a WACC-derived discount rate of 12.2% (Beta of 1.4, equity risk premium of 6.7%). We adjust each indication for probability of success with glabellar lines at 85%, cervical dystonia at 80%, plantar fasciitis at 25%, chronic migraine at 35% and upper limb spasticity at 80%." (2/14/2019)

Has Revance Therapeutics been receiving favorable news coverage?

News articles about RVNC stock have trended somewhat negative on Friday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Revance Therapeutics earned a news impact score of -1.2 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Revance Therapeutics.

Are investors shorting Revance Therapeutics?

Revance Therapeutics saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 6,590,000 shares, an increase of 9.8% from the December 15th total of 6,000,000 shares. Based on an average trading volume of 613,200 shares, the days-to-cover ratio is presently 10.7 days. Approximately 16.9% of the company's shares are short sold. View Revance Therapeutics' Current Options Chain.

Who are some of Revance Therapeutics' key competitors?

What other stocks do shareholders of Revance Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Revance Therapeutics investors own include Evolus (EOLS), Exelixis (EXEL), Intercept Pharmaceuticals (ICPT), Myovant Sciences (MYOV), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Merck & Co., Inc. (MRK), Fate Therapeutics (FATE), Gilead Sciences (GILD) and Viking Therapeutics (VKTX).

Who are Revance Therapeutics' key executives?

Revance Therapeutics' management team includes the folowing people:
  • Mr. L. Daniel Browne, Co-Founder, Pres, CEO & Director (Age 57)
  • Mr. Tobin C. Schilke, CFO & Principal Accounting Officer (Age 44)
  • Dr. Abhay Joshi, Chief Operating Officer (Age 56)
  • Ms. Caryn Gordon McDowell, Sr. VP, Gen. Counsel & Corp. Sec. (Age 49)
  • Ms. Jeanie D. Herbert, Sr. Director of Investor Relations & Corp. Communications

Who are Revance Therapeutics' major shareholders?

Revance Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (0.55%) and Nisa Investment Advisors LLC (0.00%). Company insiders that own Revance Therapeutics stock include Cyril Allouche, L Daniel Browne, Lauren P Silvernail and Phyllis Gardner. View Institutional Ownership Trends for Revance Therapeutics.

Which institutional investors are selling Revance Therapeutics stock?

RVNC stock was sold by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC. Company insiders that have sold Revance Therapeutics company stock in the last year include Cyril Allouche and L Daniel Browne. View Insider Buying and Selling for Revance Therapeutics.

Which institutional investors are buying Revance Therapeutics stock?

RVNC stock was bought by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB. View Insider Buying and Selling for Revance Therapeutics.

How do I buy shares of Revance Therapeutics?

Shares of RVNC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Revance Therapeutics' stock price today?

One share of RVNC stock can currently be purchased for approximately $22.47.

How big of a company is Revance Therapeutics?

Revance Therapeutics has a market capitalization of $1.01 billion and generates $3.73 million in revenue each year. The biopharmaceutical company earns $-142,570,000.00 in net income (profit) each year or ($3.94) on an earnings per share basis. Revance Therapeutics employs 170 workers across the globe.View Additional Information About Revance Therapeutics.

What is Revance Therapeutics' official website?

The official website for Revance Therapeutics is http://www.revance.com/.

How can I contact Revance Therapeutics?

Revance Therapeutics' mailing address is 7555 GATEWAY BLVD., NEWARK CA, 94560. The biopharmaceutical company can be reached via phone at 510-742-3400 or via email at [email protected]


MarketBeat Community Rating for Revance Therapeutics (NASDAQ RVNC)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  322 (Vote Outperform)
Underperform Votes:  303 (Vote Underperform)
Total Votes:  625
MarketBeat's community ratings are surveys of what our community members think about Revance Therapeutics and other stocks. Vote "Outperform" if you believe RVNC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RVNC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/17/2020 by MarketBeat.com Staff

Featured Article: Market Indexes

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel